Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Quarter 4 2025 showed robust advancements in the nephrology field, including FDA news, trial updates, and featured content. 

Q4 2025 Recap: Nephrology News and Updates

C3G treatment advances in 2025 with FDA approvals of iptacopan and pegcetacoplan, offering disease-modifying options


C3 Glomerulopathy in 2025: Year in Review

In 2025, FDA approvals, pivotal trials, and emerging therapies shifted nephrology care toward precision and mechanism-driven kidney medicine.


Nephrology in 2025: Year in Review

A multinational survey suggests even slowly progressing C3G and IC-MPGN substantially affect patients, caregivers, and healthcare systems.


C3G, IC-MPGN Report A Disruptive Burden Regardless of Slowed Disease Progression 

Bomback, MD, MPH answers HCPLive’s questions regarding phase 3 VALIANT results and pegcetacoplan’s therapeutic ability in C3G and IC-MPGN. 

Phase 3 VALIANT Results for Pegcetacoplan In C3G, IC-MPGN, With Andrew Bomback, MD

A curated recap of 8 impactful trial updates from the American Society of Nephrology Kidney Week 2025.

Kidney Week 2025 Recap: 8 Trial Updates to Know in Nephrology

ASN 2025 VALIANT data on pegcetacoplan show proteinuria reduction, including remission or reduction, in adolescents with C3G and IC-MPGN.


VALIANT: Pegcetacoplan Shows Sustained Efficacy in C3G and IC-MPGN, With Carla Nester, MD 

Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.

ASN Kidney Week 2025 Preview: 5 Phase 3 Trials to Know

The phase 3 data reinforce iptacopan’s safety and efficacy in C3G and support its recent US Food and Drug Administration approval for this indication.

APPEAR-C3G: Iptacopan Shows Proteinuria Reduction, eGFR Benefits in C3G

The Q3 recap for nephrology spotlights key FDA decisions, new KDIGO IgA nephropathy guidelines, and other top renal news and research.

Q3 2025 Recap: Nephrology News and Updates

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.